[Antiretroviral drugs in severe acute respiratory syndrome].
Identifieur interne : 003C26 ( Main/Exploration ); précédent : 003C25; suivant : 003C27[Antiretroviral drugs in severe acute respiratory syndrome].
Auteurs : Yazdan Yazdanpanah ; Benoît GuérySource :
- Presse medicale (Paris, France : 1983) [ 0755-4982 ] ; 2006.
Descripteurs français
- KwdFr :
- Agents antiVIH (usage thérapeutique), Antirétroviraux (administration et posologie), Antirétroviraux (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Association de médicaments, Essais cliniques comme sujet, Humains, Infections à VIH (traitement médicamenteux), Inhibiteurs de protéases (administration et posologie), Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (usage thérapeutique), Lopinavir, Protéines de fusion virale (antagonistes et inhibiteurs), Pyrimidinones (administration et posologie), Pyrimidinones (pharmacologie), Pyrimidinones (usage thérapeutique), Ribavirine (administration et posologie), Ribavirine (usage thérapeutique), Ritonavir (administration et posologie), Ritonavir (pharmacologie), Ritonavir (usage thérapeutique), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Études de cohortes.
- MESH :
- administration et posologie : Antirétroviraux, Antiviraux, Inhibiteurs de protéases, Pyrimidinones, Ribavirine, Ritonavir.
- antagonistes et inhibiteurs : Protéines de fusion virale.
- pharmacologie : Inhibiteurs de protéases, Pyrimidinones, Ritonavir.
- traitement médicamenteux : Infections à VIH, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Agents antiVIH, Antirétroviraux, Antiviraux, Inhibiteurs de protéases, Pyrimidinones, Ribavirine, Ritonavir.
- virologie : Syndrome respiratoire aigu sévère.
- Association de médicaments, Essais cliniques comme sujet, Humains, Lopinavir, Syndrome respiratoire aigu sévère, Virus du SRAS, Études de cohortes.
English descriptors
- KwdEn :
- Anti-HIV Agents (therapeutic use), Anti-Retroviral Agents (administration & dosage), Anti-Retroviral Agents (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Clinical Trials as Topic, Cohort Studies, Drug Therapy, Combination, HIV Infections (drug therapy), Humans, Lopinavir, Protease Inhibitors (administration & dosage), Protease Inhibitors (pharmacology), Protease Inhibitors (therapeutic use), Pyrimidinones (administration & dosage), Pyrimidinones (pharmacology), Pyrimidinones (therapeutic use), Ribavirin (administration & dosage), Ribavirin (therapeutic use), Ritonavir (administration & dosage), Ritonavir (pharmacology), Ritonavir (therapeutic use), SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Viral Fusion Proteins (antagonists & inhibitors).
- MESH :
- chemical , administration & dosage : Anti-Retroviral Agents, Antiviral Agents, Protease Inhibitors, Pyrimidinones, Ribavirin, Ritonavir.
- chemical , antagonists & inhibitors : Viral Fusion Proteins.
- chemical , pharmacology : Protease Inhibitors, Pyrimidinones, Ritonavir.
- chemical , therapeutic use : Anti-HIV Agents, Anti-Retroviral Agents, Antiviral Agents, Protease Inhibitors, Pyrimidinones, Ribavirin, Ritonavir.
- drug effects : SARS Virus.
- drug therapy : HIV Infections, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Clinical Trials as Topic, Cohort Studies, Drug Therapy, Combination, Humans, Lopinavir.
Abstract
Inhibition of viral assembly (protease inhibitors) and of fusion of viral and target membranes (fusion inhibitors) are general approaches to antiviral treatment, not specific for HIV. Nonetheless, the agents that induce these phenomena are most often specific for a given virus or virus family. Drugs developed for HIV treatment were reevaluated for use against severe acute respiratory syndrome-coronavirus (SARS-CoV) during and after the epidemic in 2003, in view of the absence of any other available treatment. Of the protease and entry inhibitors approved for treating HIV-infected patients, none was effective against SARS-CoV, although in vitro activity against this virus was reported for the protease inhibitor lopinavir/ritonavir, in results that have not been confirmed in the most recent studies. The epidemiologic methods used to assess this drug's efficacy are not robust. Preliminary results for SARS treatment with protease and entry inhibitors, although at early stages of development, are promising.
DOI: 10.1016/s0755-4982(06)74531-6
PubMed: 16462674
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002353
- to stream PubMed, to step Curation: 002353
- to stream PubMed, to step Checkpoint: 001F16
- to stream Ncbi, to step Merge: 001369
- to stream Ncbi, to step Curation: 001369
- to stream Ncbi, to step Checkpoint: 001369
- to stream Main, to step Merge: 003D84
- to stream Main, to step Curation: 003C26
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Antiretroviral drugs in severe acute respiratory syndrome].</title>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation><nlm:affiliation>Service universitaire des maladies infectieuses et du voyageur, Centre Hospitalier de Tourcoing, Faculté de Médecine de Lille. yyazdan@yahoo.com</nlm:affiliation>
<wicri:noCountry code="subField">Faculté de Médecine de Lille</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoît" last="Guéry">Benoît Guéry</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16462674</idno>
<idno type="pmid">16462674</idno>
<idno type="doi">10.1016/s0755-4982(06)74531-6</idno>
<idno type="wicri:Area/PubMed/Corpus">002353</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002353</idno>
<idno type="wicri:Area/PubMed/Curation">002353</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002353</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F16</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F16</idno>
<idno type="wicri:Area/Ncbi/Merge">001369</idno>
<idno type="wicri:Area/Ncbi/Curation">001369</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001369</idno>
<idno type="wicri:doubleKey">0755-4982:2006:Yazdanpanah Y:antiretroviral:drugs:in</idno>
<idno type="wicri:Area/Main/Merge">003D84</idno>
<idno type="wicri:Area/Main/Curation">003C26</idno>
<idno type="wicri:Area/Main/Exploration">003C26</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Antiretroviral drugs in severe acute respiratory syndrome].</title>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation><nlm:affiliation>Service universitaire des maladies infectieuses et du voyageur, Centre Hospitalier de Tourcoing, Faculté de Médecine de Lille. yyazdan@yahoo.com</nlm:affiliation>
<wicri:noCountry code="subField">Faculté de Médecine de Lille</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoît" last="Guéry">Benoît Guéry</name>
</author>
</analytic>
<series><title level="j">Presse medicale (Paris, France : 1983)</title>
<idno type="ISSN">0755-4982</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (therapeutic use)</term>
<term>Anti-Retroviral Agents (administration & dosage)</term>
<term>Anti-Retroviral Agents (therapeutic use)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Cohort Studies</term>
<term>Drug Therapy, Combination</term>
<term>HIV Infections (drug therapy)</term>
<term>Humans</term>
<term>Lopinavir</term>
<term>Protease Inhibitors (administration & dosage)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protease Inhibitors (therapeutic use)</term>
<term>Pyrimidinones (administration & dosage)</term>
<term>Pyrimidinones (pharmacology)</term>
<term>Pyrimidinones (therapeutic use)</term>
<term>Ribavirin (administration & dosage)</term>
<term>Ribavirin (therapeutic use)</term>
<term>Ritonavir (administration & dosage)</term>
<term>Ritonavir (pharmacology)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS Virus (drug effects)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Viral Fusion Proteins (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (usage thérapeutique)</term>
<term>Antirétroviraux (administration et posologie)</term>
<term>Antirétroviraux (usage thérapeutique)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association de médicaments</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Inhibiteurs de protéases (administration et posologie)</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Inhibiteurs de protéases (usage thérapeutique)</term>
<term>Lopinavir</term>
<term>Protéines de fusion virale (antagonistes et inhibiteurs)</term>
<term>Pyrimidinones (administration et posologie)</term>
<term>Pyrimidinones (pharmacologie)</term>
<term>Pyrimidinones (usage thérapeutique)</term>
<term>Ribavirine (administration et posologie)</term>
<term>Ribavirine (usage thérapeutique)</term>
<term>Ritonavir (administration et posologie)</term>
<term>Ritonavir (pharmacologie)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS ()</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Retroviral Agents</term>
<term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
<term>Pyrimidinones</term>
<term>Ribavirin</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
<term>Pyrimidinones</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Anti-Retroviral Agents</term>
<term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
<term>Pyrimidinones</term>
<term>Ribavirin</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antirétroviraux</term>
<term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
<term>Pyrimidinones</term>
<term>Ribavirine</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines de fusion virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
<term>Pyrimidinones</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
<term>Antirétroviraux</term>
<term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
<term>Pyrimidinones</term>
<term>Ribavirine</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Cohort Studies</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Lopinavir</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Lopinavir</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
<term>Études de cohortes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Inhibition of viral assembly (protease inhibitors) and of fusion of viral and target membranes (fusion inhibitors) are general approaches to antiviral treatment, not specific for HIV. Nonetheless, the agents that induce these phenomena are most often specific for a given virus or virus family. Drugs developed for HIV treatment were reevaluated for use against severe acute respiratory syndrome-coronavirus (SARS-CoV) during and after the epidemic in 2003, in view of the absence of any other available treatment. Of the protease and entry inhibitors approved for treating HIV-infected patients, none was effective against SARS-CoV, although in vitro activity against this virus was reported for the protease inhibitor lopinavir/ritonavir, in results that have not been confirmed in the most recent studies. The epidemiologic methods used to assess this drug's efficacy are not robust. Preliminary results for SARS treatment with protease and entry inhibitors, although at early stages of development, are promising.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Guery, Benoit" sort="Guery, Benoit" uniqKey="Guery B" first="Benoît" last="Guéry">Benoît Guéry</name>
<name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:16462674 |texte= [Antiretroviral drugs in severe acute respiratory syndrome]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16462674" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |